Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study - 10/08/11
, Jan AJW Kluytmans, ProfMD e, f, Hetty EM Blok, MSc b, Ellen M Mascini, MD g, Robin FJ Benus, MD h, Alexandra T Bernards, MD i, Ed J Kuijper, MD i, Maurine A Leverstein-van Hall, MD b, Arjan R Jansz, MD j, Bartelt M de Jongh, MD k, Gerard J van Asselt, MD l, Ine HME Frenay, MD m, Steven FT Thijsen, MD n, Simon NM Conijn o, Jan A Kaan, MD p, Jan P Arends, MD h, Patrick DJ Sturm, MD q, Martin CJ Bootsma, PhD b, Marc JM Bonten, ProfMD b, cSummary |
Background |
Previously, we assessed selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD) on survival and prevention of bacteraemia in patients in intensive-care units. In this analysis, we aimed to assess effectiveness of these interventions for prevention of respiratory tract colonisation and bacteraemia with highly resistant microorganisms acquired in intensive-care units.
Methods |
We did an open-label, clustered group-randomised, crossover study in 13 intensive-care units in the Netherlands between May, 2004, and July, 2006. Participants admitted to intensive-care units with an expected duration of mechanical ventilation of more than 48 h or an expected stay of more than 72 h received SOD (topical tobramycin, colistin, and amphotericin B in the oropharynx), SDD (SOD antibiotics in the oropharynx and stomach plus 4 days’ intravenous cefotaxime), or standard care. The computer-randomised order of study regimens was applied by an independent clinical pharmacist who was masked to intensive-care-unit identity. We calculated crude odds ratios (95% CI) for rates of bacteraemia or respiratory tract colonisation with highly resistant microorganisms in patients who stayed in intensive-care units for more than 3 days (ie, acquired infection). This trial is registered at isrctn.org, number ISRCTN35176830.
Findings |
Data were available for 5927 (>99%) of 5939 patients, of whom 5463 (92%) were in intensive-care units for more than 3 days. 239 (13%) of 1837 patients in standard care acquired bacteraemia after 3 days, compared with 158 (9%) of 1758 in SOD (odds ratio 0·66, 95% CI 0·53–0·82), and 124 (7%) of 1868 in SDD (0·48, 0·38–0·60). Eight patients acquired bacteraemia with highly resistant microorganisms during SDD, compared with 18 patients (with 19 episodes) during standard care (0·41, 0·18–0·94; rate reduction [RR] 59%, absolute risk reduction [ARR] 0·6%) and 20 during SOD (0·37, 0·16–0·85; RR 63%, ARR 0·7%). Of the patients staying in intensive-care units for more than 3 days, we obtained endotracheal aspirate cultures for 881 (49%) patients receiving standard care, 886 (50%) receiving SOD, and 828 (44%) receiving SDD. 128 (15%) patients acquired respiratory tract colonisation with highly resistant microorganisms during standard care, compared with 74 (8%) during SDD (0·58, 0·43–0·78; RR 38%, ARR 5·5%) and 88 (10%) during SOD (0·65, 0·49–0·87; RR 32%, ARR 4·6%). Acquired respiratory tract colonisation with Gram-negative bacteria or cefotaxime-resistant and colistin-resistant pathogens was lowest during SDD.
Interpretation |
Widespread use of SDD and SOD in intensive-care units with low levels of antibiotic resistance is justified.
Funding |
None.
Le texte complet de cet article est disponible en PDF.Plan
Vol 11 - N° 5
P. 372-380 - mai 2011 Retour au numéro
Article précédent
- Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
- Linda Wittkop, Huldrych F Günthard, Frank de Wolf, David Dunn, Alessandro Cozzi-Lepri, Andrea de Luca, Claudia Kücherer, Niels Obel, Viktor von Wyl, Bernard Masquelier, Christoph Stephan, Carlo Torti, Andrea Antinori, Federico García, Ali Judd, Kholoud Porter, Rodolphe Thiébaut, Hannah Castro, Ard I van Sighem, Céline Colin, Jesper Kjaer, Jens D Lundgren, Roger Paredes, Anton Pozniak, Bonaventura Clotet, Andrew Phillips, Deenan Pillay, Geneviève Chêne, for the EuroCoord-CHAIN study group †
- Metallo-β-lactamases: a last frontier for β-lactams?
- Giuseppe Cornaglia, Helen Giamarellou, Gian Maria Rossolini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?